Alpharma Inc. (Fort Lee, NJ) and Medical Science Systems, Inc. (MSSI; San Antonio, TX) have announced an agreement where Alpharma has acquired the rights to promote and distribute PST, MSSI's genetic susceptibility test for periodontal disease, in ten countries in Europe. The countries are Austria, Denmark, Finland, Germany, Ireland, Norway, Portugal, Sweden, Switzerland, and the United Kingdom.
Under the terms of the agreement, the International Pharmaceutical Division of Alpharma would be responsible for all sales and marketing activities throughout the ten territories. Medical Science Systems would be responsible for providing technical support and the laboratory testing service. Medical Science Systems would receive an upfront payment, milestone payments and a share of the revenues, according to a press release.
PST, a test predictive of risk for periodontal disease, is currently available in the United States.